🔎 Trials Near Me

Beranda › Obesitas › Tennessee

Uji klinis Obesitas di Tennessee

38 studi untuk Obesitas mencari peserta di lokasi di Tennessee.

Kota di Tennessee

Teks studi resmi (Bahasa Inggris)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

  • Holston Medical Group - Bristol /ID# 282045, Bristol
  • New Phase Research & Development /ID# 282131, Knoxville
  • Summit Medical Group- Halls Family Physicians /ID# 282435, Knoxville
  • dan 1 lainnya
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07752979

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

  • M3 Wake Research Chattanooga, Chattanooga
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07533175

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  • LifeDoc Health, Memphis
Menerima pesertaFase 3
Usia 8 hingga 18 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07253285

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

  • AMR Clinical, Nashville
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07837973

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Gastroenterology Center Of The Midsouth, Cordova
Menerima pesertaFase 3
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06937099

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  • Vanderbilt Health One Hundred Oaks, Nashville
Menerima pesertaFase 3
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06672549

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Gastroenterology Center Of The Midsouth, Cordova
Menerima pesertaFase 3
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06937086

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  • Research Site, Franklin
  • Research Site, Jackson
  • Research Site, Knoxville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07784270

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Stern Cardiovascular Foundation Inc, Germantown
  • Accellacare of Knoxville, Knoxville
  • Cardiovascular Research of Knoxville North Knoxville Medical Center, Powell
  • dan 1 lainnya
Menerima pesertaFase 3
Usia 45 hingga 99 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  • AMR Clinical, Nashville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07321886

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  • Quality Medical Research, Nashville
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07589608

Transition to Ambulatory Bariatric Surgery (TABS) Trial

  • Vanderbilt University Medical Center, Nashville
Menerima peserta
Usia 25 hingga 55 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07011628

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Memphis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Memphis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07743450

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  • Apex Research Foundation, LLC, Jackson
  • The Jackson Clinic PA, Jackson
  • Parkway Cardiology Associates, Oak Ridge
  • dan 2 lainnya
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07037459

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  • Innovative Clinical Research, Clarksville
  • Clinical Research Associates, Nashville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07351045

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Nashville
Menerima pesertaFase 3Sukarelawan sehat diterima
Usia 18 hingga 79 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07654374

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  • Quality Medical Research, Nashville
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06143956

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailea Clinical Site, Memphis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • New Phase Research and Development, Knoxville
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07684235

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  • Kailera Clinical Site, Chattanooga
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07284875

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT05972564

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  • Research Site, Kingsport
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT07784725

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  • Balad Hlth Sys-Welmont CardCVA, Greeneville
  • The Jackson Clinic, PA, Jackson
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07567001

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Knoxville
Menerima pesertaFase 3
Usia 18 hingga 79 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT07654361

Atomoxetine in Melanocortin Obesity Syndrome

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaFase 2
Usia 6 ke atas · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT06899178

A Study to Improve Skeletal Muscle in Veterans With HIV

  • Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
Menerima peserta
Usia 20 hingga 80 · Pria · Diperbarui 26 Jun 2026 · NCT06845046

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

  • Holston Medical Group_Bristol, Bristol
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Jun 2026 · NCT07607587

Daily Eating Patterns for Total Health Study

  • Healthy Eating and Activity Laboratory, Knoxville
Menerima peserta
Usia 25 hingga 60 · Semua jenis kelamin · Diperbarui 15 Jun 2026 · NCT06455995

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

  • MBX Biosciences Investigational Site, Knoxville
Menerima pesertaFase 1
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 9 Jun 2026 · NCT07142707

EBT Fruit and Vegetable Prescription

  • Cherokee Health Systems, Dameron Avenue Pedatrics, Knoxville
Menerima pesertaSukarelawan sehat diterima
Usia 4 hingga 10 · Semua jenis kelamin · Diperbarui 9 Jun 2026 · NCT05028205

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

  • St. Jude Children's Research Hospital, Memphis
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Jun 2026 · NCT07228741

Metabolic Effects of Angiotensin-(1-7)

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaFase 1
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT02646475

Sympathetic Mechanisms in Obesity-Crossover Design

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaFase 1/2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 27 Feb 2026 · NCT05312892

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

  • Vanderbilt University Medical Center (Part C only), Nashville
Menerima pesertaFase 1/2Sukarelawan sehat diterima
Usia 12 hingga 65 · Semua jenis kelamin · Diperbarui 22 Des 2025 · NCT06239116

Tirzepatide in PWS, HO and GNSO

  • Vanderbilt University Medical Center, Nashville
Menerima pesertaFase 4
Usia 18 hingga 26 · Semua jenis kelamin · Diperbarui 16 Sep 2025 · NCT06901245

Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia

  • University of Tennessee Medical Center, Knoxville
Menerima pesertaStudi observasional
Usia 18 hingga 45 · Wanita · Diperbarui 10 Sep 2025 · NCT06802861

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.